



01179/1

## JOINT DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As the below named inventors, we hereby declare that:

Our residences, post office addresses and citizenships are as stated below next to our names;

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE EXPRESSION

- ☐ is attached hereto.
- ☐ was filed on \_\_\_\_\_ as Application Serial No. \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).
- ☐ as filed under the Patent Cooperation Treaty (PCT) and accorded International Application No. \_\_\_\_\_, filed \_\_\_\_\_, and amended on \_\_\_\_\_ (if any).

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We hereby acknowledge the duty to disclose information which is material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

### Prior Foreign Application(s)

We hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Country	Application No.	Date of Filing (day month year)	Date of Issue (day month year)	Priority Claimed Under 35 U.S.C. §119

### Prior United States Provisional Application(s)

We hereby claim priority benefits under Title 35, United States Code, §119(e)(1) of any U.S. provisional application listed below:

U.S. Provisional Application No.	Date of Filing (day month year)	Priority Claimed Under 35 U.S.C. §119(e)(1)
60/413,549	September 25, 2002	

**Prior United States Application(s)**

We hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Date of Filing (Day, Month, Year)	Status — Patented, Pending, Abandoned
TBA	TBA	

**Power of Attorney**

And we hereby appoint, both jointly and severally, as our attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith the following attorneys and agents, their registration numbers being listed after their names:


BAUER, S. Christopher	42,307	KING, Karen B.	41,898	SCHUH, Joseph R.	48,180
CHAPPELL, Julie	46,612	LUMB, Trevor J.	28,567	WARNER, James M.	45,199
FORBES, James C.	39,457	POLSTER, Philip B., II	43,864	WILLIAMS, Scott A.	39,876
KEANE, J. Timothy	27,808	POLSTER, Rachel	47,004		

All correspondence and telephone communications should be addressed to:

Pharmacia Corporation  
Global Patent Department  
P. O. Box 1027  
Mail Zone MC5  
St. Louis, MO 63141

Tel: (314) 274-7354  
Fax: (314) 274-9095

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature 

Date Oct. 2, 2003

Full Name of First Inventor Gierse James K.  
Family Name First Given Name Second Given Name  
Residence St. Louis, Missouri 63119 Citizenship U.S.A.

Post Office Address 141 Clara Avenue, St. Louis, Missouri 63119



CERTIFICATE OF MAILING BY FIRST-CLASS MAIL (37 CFR 1.8)

Serial No: 10/671,395  
Filing Date: September 25, 2003  
Group Art Unit: Not Assigned  
Docket No: 01179/1  
Invention: Antisense Modulation of Microsomal Prostaglandin E2 Synthase  
Expression

Date of Deposit: November 24, 2003

I hereby certify that these papers or fee is being deposited with the United States Post Office to Addressee service under 37 CFR 1.10 & 1.8 on the date indicated above and is addressed to Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450:

Transmittal Letter  
Joint Declaration and Power of Attorney for Patent Application  
Return Postcard

Linda Haley  
(Typed or printed name of person mailing paper or fee)

*Linda Haley*  
(Signature of person mailing paper or fee)